- NASDAQ: INO is set to end the week with a steady upside gain.
- Inovio Pharmaceuticals Inc is still in the COVID-19 vaccine race amid two major advantages.
- The pharma firm has other products in its pipeline which make it a potentially profitable long-term investment.
With Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) try to beat each other with efficacy levels of their COVID-19 vaccines, it may be easy to forget about other efforts such as that of Inovio Pharmaceuticals Inc (NASDAQ: INO). The Plymouth Meeting, Pennsylvania-based pharma firm is also in the race to develop coronavirus immunization – a contest that may have more than one or two winners.
Inovio has received permission to begin a Phase 2/3 trial called Innovate on November 16. While the firm's INO-4800's vaccine candidate needs two doses – like the others – it has other advantages.
First, the inoculation can be stored at room temperature for a full year, easing its distribution and storage. Costs are also likely to be lower. Another factor in its favor – yet currently questioned by the regulator – is the ability to deliver the dose directly through the skin. Inovio's Cellectra 2000 device is needed for administering the vaccine, yet it is simpler than an outright injection.
Inovio's Phase 1 trial has shown that the immunization candidate prompts the creation of both antibodies and T-cells. Even if the first vaccines that Americans and others receive do not come from Inovio, the easy storage and application of this protection could be used as a seasonal boost later on.
Moreover, the company uses its DNA approach to develop other drugs. These include cancer, infectious disease, and human papillomavirus. That makes NASDAQ: INO a potential long-term investment.
Inovio Pharmaceuticals Stock
NASDAQ: INO is quoted at $11.20 in Friday's pre-market trading. Shares are up some 1.63% after dropping by 0.1% on Thursday. Calm trading is relatively new to Inovio's shares, which have ranged between the $8 handle the $12 one during November.
The firm is valued at $1.87 billion, making it a small company in comparison to other pharmaceutical firms. There is substantial room to go toward the 52-week high of $33.79.
More
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD clings to daily gains above 1.0650
EUR/USD gained traction and turned positive on the day above 1.0650. The improvement seen in risk mood following the earlier flight to safety weighs on the US Dollar ahead of the weekend and helps the pair push higher.
GBP/USD recovers toward 1.2450 after UK Retail Sales data
GBP/USD reversed its direction and advanced to the 1.2450 area after touching a fresh multi-month low below 1.2400 in the Asian session. The positive shift seen in risk mood on easing fears over a deepening Iran-Israel conflict supports the pair.
Gold holds steady at around $2,380 following earlier spike
Gold stabilized near $2,380 after spiking above $2,400 with the immediate reaction to reports of Israel striking Iran. Meanwhile, the pullback seen in the US Treasury bond yields helps XAU/USD hold its ground.
Bitcoin Weekly Forecast: BTC post-halving rally could be partially priced in Premium
Bitcoin price shows no signs of directional bias while it holds above $60,000. The fourth BTC halving is partially priced in, according to Deutsche Bank’s research.
Week ahead – US GDP and BoJ decision on top of next week’s agenda
US GDP, core PCE and PMIs the next tests for the Dollar. Investors await BoJ for guidance about next rate hike. EU and UK PMIs, as well as Australian CPIs also on tap.